NCT07178639 - Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Macular OedemaCataract SurgeryNSAID (Non-Steroidal Anti-Inflammatory Drug)

Interventions

DRUG

Bromfenac 0.09 % Ophthalmic Solution

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.

DRUG

Nepafenac 0.3% Oph Susp

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.

DRUG

diclofenac 0.1% ophthalmic susp.

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.

Trial Locations (1)

28002

RECRUITING

Oblastní nemocnice Kolín a.s., Kolín